Pricing Log in Create free account

INmune Bio, Inc. (INMB) vs IRulya Therapeutics Inc. (IRLA)

INmune Bio, Inc. and IRulya Therapeutics Inc. are both Biotechnology companies. INmune Bio, Inc. and IRulya Therapeutics Inc. are of similar size ($32.6M and $29.8M). Across the 9 metrics below, IRulya Therapeutics Inc. leads on 5 and INmune Bio, Inc. on 4.

Valuation

Metric INMB IRLA Biotechnology median
P/E n/m n/m 10.60
P/S 221.67 n/m 9.40
P/B 1.47 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 121.37 n/m 9.02
Earnings yield (59.82%) (463.25%) (32.88%)
Free cash flow yield (54.91%) (25.09%) (23.13%)

Profitability

Metric INMB IRLA Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (74.82%) 784.09% (51.96%)
Return on assets (57.08%) (76.68%) (46.06%)
Return on invested capital (646.94%) 0.00% 0.00%

Growth

Metric INMB IRLA Biotechnology median
Revenue growth (TTM) (51.61%) — 6.76%
EPS growth (last fiscal year) 11.85% (28.24%) 29.88%
Revenue growth, 5-year CAGR 35.37% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INMB IRLA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.04 14.52 4.97
Net debt to EBITDA 0.52 0.00 1.01

Dividend

Metric INMB IRLA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric INMB IRLA Biotechnology median
Market cap 32.61m 29.81m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack